Sugi Predict

Sugi Predict / Compounds / SCHEMBL21069592

SCHEMBL21069592

SCHEMBL21069592

CC(C)(C)OC(=O)NCCCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O

nearest known ligand 0.90

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 7/20 0.90
▸ DDB1 Q16531 5/20 0.90
▸ STAT3 P40763 6/20 0.65
▸ CA2 P00918 2/20 0.61
▸ GRAMD1A Q96CP6 4/20 0.60
▸ HDAC8 Q9BY41 1/20 0.58
▸ HDAC3 O15379 2/20 0.57
▸ HDAC1 Q13547 2/20 0.57
▸ HDAC2 Q92769 2/20 0.57
▸ NCOR2 Q9Y618 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31031416 1.00 CRBN (0.90) CRBNDDB1STAT3CA2GRAMD1A
SCHEMBL21106634 0.99 CRBN (0.89) CRBNDDB1STAT3CA2GRAMD1A
SCHEMBL22511880 0.99 CRBN (0.89) CRBNDDB1STAT3CA2GRAMD1A
SCHEMBL22511903 0.99 CRBN (0.89) CRBNDDB1STAT3CA2GRAMD1A
SCHEMBL25123413 0.99 CRBN (0.89) CRBNDDB1STAT3CA2GRAMD1A
SCHEMBL25123821 0.99 CRBN (0.89) CRBNDDB1STAT3CA2GRAMD1A
SCHEMBL23884233 0.99 CRBN (0.89) CRBNDDB1STAT3CA2GRAMD1A
SCHEMBL23884311 0.99 CRBN (0.89) CRBNDDB1STAT3CA2GRAMD1A
SCHEMBL21760067 0.99 CRBN (0.89) CRBNDDB1STAT3CA2GRAMD1A
SCHEMBL20188589 0.99 CRBN (0.89) CRBNDDB1STAT3CA2GRAMD1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
WO-2025216628-A1 PROTAC COMPOUNDS UNIVERSITEIT LEIDEN (NL) 2025-10-16 — — WO disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
US-12404285-B2 KRAS G12D proteolysis targeting chimeras PAQ Therapeutics Inc. (US) 2025-09-02 — — US disclosed
EP-4598905-A2 CEREBLON-RECRUITING BCL-XL/BCL-2 DUAL DEGRADERS University of Florida Research Foundation, Incorporated (US) 2025-08-13 — — EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 — — EP disclosed
US-20250121073-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-04-17 — — US disclosed
EP-4519273-A1 KRAS G12D PROTEOLYSIS TARGETING CHIMERAS Paq Therapeutics Inc. (US) 2025-03-12 — — EP disclosed
US-20250051364-A1 KRAS G12D Proteolysis Targeting Chimeras PAQ Therapeutics Inc. (US) 2025-02-13 — — US disclosed
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-02 — — US disclosed
US-20210363146-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE CULLGEN (SHANGHAI), INC. (CN) 2021-11-25 — — US disclosed
US-20210315999-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE CULLGEN (SHANGHAI), INC. (CN) 2021-10-14 — — US disclosed
WO-2021022076-A1 MOLECULES AND METHODS RELATED TO TREATMENT OF UNCONTROLLED CELLULAR PROLIFERATION ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2021-02-04 — — WO disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
EP-3731869-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2020-11-04 — — EP disclosed
WO-2020200291-A1 COMPOUNDS AND METHODS OF TREATING CANCERS CULLGEN (SHANGHAI) , INC. (CN) 2020-10-08 — — WO disclosed
WO-2020038415-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE CULLGEN (SHANGHAI), INC. (CN) 2020-02-27 — — WO disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10874743-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 CRBN 187/4885DDB1 1267/4885STAT3 145/4885
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CRBN 187/4885DDB1 1267/4885STAT3 145/4885
US-20250051364-A1 KRAS G12D Proteolysis Targeting Chimeras KRAS, NRAS, HRAS CRBN 51/4885DDB1 1063/4885STAT3 963/4885
US-20250121073-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CRBN 187/4885DDB1 1267/4885STAT3 145/4885
US-12404285-B2 KRAS G12D proteolysis targeting chimeras KRAS, NRAS, HRAS CRBN 51/4885DDB1 1063/4885STAT3 963/4885
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CRBN 187/4885DDB1 1267/4885STAT3 145/4885
US-20210363146-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE MUSK, NTRK1, ERBB2 CRBN 194/4885DDB1 418/4885STAT3 4012/4885
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CRBN 187/4885DDB1 1267/4885STAT3 145/4885
US-20210315999-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE MUSK, ERBB2, NTRK1 CRBN 330/4885DDB1 480/4885STAT3 3381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.